Free Trial Information
BioCentury | Mar 3, 2016
Distillery Therapeutics

Therapeutics: Corticotropin-releasing factor receptor 1 (CRHR1; CRFR1)

...with an IC50 of 88 nM. In mice, the compound decreased interactions between CRHR1 and corticotrophin-releasing factor...
Read More
BioCentury | Dec 12, 2011
Emerging Company Profile

Sera Prognostics: Predicting preemies

...May in the American Journal of Obstetrics and Gynecology . The six additional biomarkers were corticotrophin-releasing factor...
Read More
BioCentury | Feb 18, 2010
Distillery Techniques

Technology: Approach

...treat neurological diseases. A choroid plexus-targeting lentiviral vector was designed to express the anxiety-associated gene corticotrophin-releasing factor...
Read More
BioCentury | Sep 20, 2004
Company News

Neurogen, Sanofi-Aventis S.A. deal

...The companies will terminate on Dec. 8, their 2001 deal to develop therapeutics against corticotrophin-releasing factor...
Read More
BioCentury | Sep 20, 2004
Finance

Ebb & Flow

...week down $0.34 to $6.35 on news that its deal with Sanofi-Aventis (Euronext:SAN; SNY) for corticotrophin-releasing factor...
Read More
BioCentury | Sep 15, 2004
Company News

Neurogen, Sanofi-Aventis ending CRF1 deal

NRGN and Sanofi - Aventis S.A. (Euronext:SAN; SNY) will terminate on Dec. 8 their 2001 deal to develop therapeutics against corticotrophin releasing factor ( CRF1 ) for stress disorders, including depression and anxiety. The original deal was between...
Read More
BioCentury | Jan 5, 2004
Company News

Neurogen, Aventis deal

NRGN received a $1 million milestone from AVE under the companies' 2001 deal to develop therapeutics against corticotrophin releasing factor ( CRF1 ). The payment was triggered by a preclinical milestone. Neurogen Corp. (NRGN), Branford, Conn....
Read More
BioCentury | Dec 24, 2001
Company News

Neurogen, Aventis deal

AVE licensed exclusive worldwide rights to NRGN's corticotrophin releasing factor ( CRF1 ) antagonist compounds, including its lead, NGD 98-2, for use in treating depression, anxiety and other stress-related disorders. NRGN will receive a $10 million upfront...
Read More
BioCentury | Dec 20, 2001
Company News

Neurogen, Aventis CRF1 deal

AVE licensed exclusive worldwide rights to NRGN's corticotrophin releasing factor ( CRF1 ) antagonist compounds, for use in treating depression, anxiety and other stress-related disorders, including lead compound NGD 98-2. NRGN will receive a $10 million upfront...
Read More
BioCentury | Jul 1, 1996
Clinical News

Corticotrophin-releasing factor data

...is planned. NTII is seeking a corporate partner. Neurobiological Technologies Inc. (NTII), Richmond, Calif. Product: Corticotrophin-releasing factor...
Read More
Items per page:
1 - 10 of 10